01CryptoKreepa
liked and voted
The Options Paper Trading Challenge has come to an end, and we're thrilled to have around 17,000 participants over the past 4 weeks!
Last week, more than 564 participants achieved virtual gains exceeding 5%, with $Advanced Micro Devices (AMD.US)$ being the most actively traded option during the earnings season.
Over 730 participants attained virtual gains exceeding 5% throughout the four-w...
![Check in on our Option Paper Trading Challenge's top performers - Week Four & Final Rank](https://ussnsimg.moomoo.com/sns_client_feed/77777007/20250211/web-1739240752338-HBSPftCQNF.jpeg/thumb?area=100&is_public=true)
![Check in on our Option Paper Trading Challenge's top performers - Week Four & Final Rank](https://ussnsimg.moomoo.com/sns_client_feed/77777007/20250211/web-1739240906867-fwFuqKsCJc.png/thumb?area=100&is_public=true)
![Check in on our Option Paper Trading Challenge's top performers - Week Four & Final Rank](https://ussnsimg.moomoo.com/sns_client_feed/77777007/20250211/web-1739240989038-ASZlfxyewA.jpeg/thumb?area=100&is_public=true)
+7
1644
179
7
01CryptoKreepa
voted
The raw materials required for technology advancement depend on both current mature technologies and emerging technologies. These materials are integral to the production of semiconductors, electronics, renewable energy systems, and other high-tech components. Some materials are already well-established in industrial use, while others are critical for technologies in their nascent stages.
Raw Materials for Current Mature Technol...
Raw Materials for Current Mature Technol...
13
1
2
01CryptoKreepa
liked
$Tiziana Life Sciences (TLSA.US)$
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
Thursday, 23rd January at 8:54 am
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engag...
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
Thursday, 23rd January at 8:54 am
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces its intention not to engag...
1
01CryptoKreepa
liked
You can Spend Rich 🤑 But YOU CAN’T SPEND WEALTH 💯
INVESTOR MINDSET followed by TRADING TIPS & TRICKS BELOW 👇🏽
• Trading is important but so is Investing for True Long Term Wealth Creation…
• BEARS SOUND SO SMART 🧠 BUT BULLS MAKE YOU MONEY 💰
• How I Trade:
✅ Bullish 🐂📈
❌ Piggyish 🐖🏈
❌ Bearish 🐻📉
All jokes aside… 🤣
Greed and Analysis Paralysis are NOT [Effective] Trading Strategies…
• Bulls 🐂📈 Make a LOT of Money 💰 Bear...
INVESTOR MINDSET followed by TRADING TIPS & TRICKS BELOW 👇🏽
• Trading is important but so is Investing for True Long Term Wealth Creation…
• BEARS SOUND SO SMART 🧠 BUT BULLS MAKE YOU MONEY 💰
• How I Trade:
✅ Bullish 🐂📈
❌ Piggyish 🐖🏈
❌ Bearish 🐻📉
All jokes aside… 🤣
Greed and Analysis Paralysis are NOT [Effective] Trading Strategies…
• Bulls 🐂📈 Make a LOT of Money 💰 Bear...
![INVEST LIKE THE 1% BILLIONAIRES & MULTIMILLIONAIRES - SIMPLE AS A DIMPLE 😏](https://ussnsimg.moomoo.com/sns_client_feed/74318574/20241116/a59989617e76f5e6d7b42f0601b2b190.jpg?area=100&is_public=true)
![INVEST LIKE THE 1% BILLIONAIRES & MULTIMILLIONAIRES - SIMPLE AS A DIMPLE 😏](https://ussnsimg.moomoo.com/sns_client_feed/74318574/20241118/a42138dd5eee96a7ac514111f7358256.jpg?area=100&is_public=true)
![INVEST LIKE THE 1% BILLIONAIRES & MULTIMILLIONAIRES - SIMPLE AS A DIMPLE 😏](https://ussnsimg.moomoo.com/sns_client_feed/74318574/20241116/b3f5870d3029c7a654346a9619440db0.jpg?area=100&is_public=true)
+11
100
76
15
01CryptoKreepa
liked
$Oncolytics Biotech (ONCY.US)$ Benzinga· 4 mins ago
Oncolytics Biotech Reveals Presentation Of Two Data Sets Through Two Abstracts Showcasing Pelareorep's Potential In Difficult-to-treat Gastrointestinal Cancers At ASCO
Oncolytics Biotech Reveals Presentation Of Two Data Sets Through Two Abstracts Showcasing Pelareorep's Potential In Difficult-to-treat Gastrointestinal Cancers At ASCO
2
01CryptoKreepa
liked
$Oncolytics Biotech (ONCY.US)$
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Monday, 23rd December at 7:00 am
Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval
Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies
SAN DIEGO and CALGARY, AB, Dec. 23, 2024...
Oncolytics Biotech® Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data
Monday, 23rd December at 7:00 am
Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approval
Advancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studies
SAN DIEGO and CALGARY, AB, Dec. 23, 2024...
1